Aus Genomic screening and clinical trials $185m

An emotional yet uplifting morning at @garvaninstitute as @angustaylormp together with @greghuntmp (not present due to another commitment), announced a joint funding agreement of $185.4min for the ground-breaking vision of Professor David Thomas and the stellar team at @garvaninstitute to facilitate the Precision Oncology Screening Platform enabling Clinical Trials (PrOSPeCT).

It is difficult not to be emotional when you stop to consider the gravity and breadth of this programme, and what it will mean to those patients living with cancer in Australia, and in particular, rare cancers such as sarcomas.  Sarcoma patients live with the uncertainty of a ‘heterogenous’ cancer (prone to constant change), and genomic screening for genetic mutations, and the discovery of therapeutic matches (personalised therapeutics)  is a critical component of working toward a cure.

Speakers included the Garvan Institute’s Mara-Jean Tilley who managed to do the impossible by putting a very polished press conference together in less than 24 hours, the ever humble Professor David Thomas, The Honourable Angus Taylor MP, Minister for Minister for Industry, Energy and Emissions Reduction, Mr Stuart Knight, General Manager Roche, Dr Tony Penna representing NSW Health, Andrew Hagger CEO, Minderoo, Richard Vines CEO of Rare Cancers Australia and Omico Chair, Paul Jeans.  Each of the speakers spoke with deep passion about the programme, and the inherent difference it would make to those who need it most.

Some of the many aims of this programme are to provide both paediatric and adult patients increased access to genomic screening, (an additional 20,000 patients), repurposed drugs and immunotherapies, to empower Australian clinical trials innovation and capacity building, and to drive pharmaceutical and biotech engagement, establishing Australia as a world leader in this space.

By expanding the current programme to accommodate 20,000 additional patients, will provide untold hope to those who will over the coming months and years, be diagnosed with cancer.

The NSW @nswhealth and Federal Government(s) @healthgovau @industrygovau are to be acknowledged and thanked for their support of this programme, @childrenscancerinstitute for their contribution to the very important paediatric and AYA component, together with
@roche and philanthropic partners @minderoofoundation @rarecancers

IMG-0090
IMG-0100 (1)
IMG-0096
previous arrow
next arrow

International Rare Disease Day 28 February, 2022


International Rare Diseases Day
Our brilliant scientists and health professionals together with investment in research can, and will make a difference to the 300 million people living with a rare disease.

As a collective our voices are strong.

We congratulate the stellar team at the Daniel Ferguson LGMD Foundation, launched today, the first organisation of its type in Australia to focus on Limb-Girdle Muscular Dystrophy in its pursuit of improving outcomes for those diagnosed.

Inter-Ewing-1 clinical trial

The Cooper Rice-Brading Foundation is delighted to be joining with The Kids Cancer Project once again, to provide funding support for a new international clinical trial for patients diagnosed with Ewing sarcoma that will be available soon to patients in Australia and New Zealand.

CRBF and TKCP join with the Federal Government Medical Research Futures Fund through Canteen and ANZCHOG, and the GPA Andrew Ursini Charitable Fund providing philanthropic support to ANZSA.

In a recent press release, CEO of The Kids Cancer Project, Owen Finegan said “The Kids’ Cancer Project and the Cooper Rice-Brading Foundation are proud to be providing funding for this exciting international clinical trial, which will help children across Australia and beyond benefit from access to new treatment strategies.”

 

Ewing sarcoma is a rare and highly aggressive tumour that forms in bone or soft tissue, which can affect all age groups, but hits our young (paediatrics, adolescents and young adults) disproportionately hard. Survival rates for localised disease currently sit between 65% – 75%, however for those patients with advanced disease, survival rates plummet as low as 25%.

INTER-EWING-1 is an international clinical trial that examines several new treatment strategies for Ewing sarcoma patients, including access to a novel agent (a tyrosine kinase inhibitor), optimising radiotherapy doses and adding “maintenance” chemotherapy at the end of other planned treatments for patients of all ages.

 

This study will involve an internationally renowned team of sarcoma researchers led by Bone Cancer Research Trust Trustee and world-renowned Consultant Paediatric Oncologist, Professor Bernadette Brennan and will be conducted throughout Europe, the United Kingdom, Israel and Australia, where Australian researchers have contributed to development of the trial.

The University of Birmingham will act as the International Sponsor for the INTER-EWING-1 trial, with ANZCHOG the National Sponsor for participating Australian and New Zealand paediatric and adult oncology centres. Associate Professor Geoff McCowage, Medical Oncologist Westmead Children’s Hospital, is Chief Investigator of this trial and has also recently joined the CRBF Medical Advisory Board, and brings a wealth of experience in sarcoma to this study.

Afternoon Sports Podcast Auction 4 Sarcoma


Congratulations to Nathan Lyon for an outstanding 400th Test wicket over the weekend!

Nathan and his has manager, Peter Lovitt, Director of the Driver Avenue Group have been loyal supporters of CRBF and the advancement of sarcoma. Both Nathan and Peter went that extra mile on a personal level for Cooper after his diagnosis with osteosarcoma, bringing joy in an otherwise very dark period of his life.

Coincidentally, Nathan has once again gone out of his way to provide a money can’t buy opportunity, to host a 10 person bowling clinic, with proceeds raised going directly to sarcoma research and patient support in Australia.

This opportunity Nathan is providing forms just part of an incredible array of prizes on offer through the Afternoon Sports Podcast Auction, where 100% of funds raised will will contribute to the Sarcoma Navigation Telephone Support Line – a critical service which will provide a free of charge additional layer of clinical assistance for patients and families in Australia.

Nathan teams with league legend and all around round good guy Benji Marshall who is offering his company for 18 holes on the golf course.

A signed rugby jersey donated by the family of Wallabies Captain Michael Hooper is also available, along with a portrait of Latrell Mitchell, painted by Cooper Tarleton an osteosarcoma survivor and indigenous artist.

Finally, a signed 2019 Ashes cricket bat donated by Todd Greenberg at Cricket Australia and a 2021 signed NSW State of Origin jersey thanks to the NSW Blues.

This auction has now commenced and will close Christmas Eve, making these items the perfect Christmas gifts for someone special!

Enormous thanks to Craig Coleman and Blair Crawford, Tim Gilbert, Shane Lee, and all at the Afternoon Sport Podcast for their hard work in bringing this together in memory of Celso Munoz, who lost his life to osteosarcoma in October.

Fergus McCulla Psychological Support Programme


Fergus Mculla was a very special young man to many, staging a courageous battle with rhabdomyosarcoma, which tragically ended in August of 2021.

The team at CRBF formed a very special bond with Fergus and his remarkable family over past years, and as a result, many of us witnessed first-hand, the resilience and positivity Fergus showed throughout his treatment .  No matter what life threw at him, his beautiful smile was never far away.

No matter what life threw at him, his beautiful smile was never far away. CRBF is delighted to announce the Fergus McCulla Psychological Support & Wellness Programme will be officially launched this month, and will be free of charge for all patients and families. Please press the banner to read more.

Fergus was also a voice for change whilst he underwent treatment, especially concerned about the level of formal support offered from the point of diagnosis and beyond. His courage was always evident in his ability to share his sarcoma journey on social media, helping others navigating the same pathway, and in doing so, providing support and a shoulder for many. Press to read more of this remarkable young man and the new CRBF programme named in his honour.

When it became time to name our psychological support programme, it was an obvious choice that it should bear Fergus’ name.

CRBF is delighted to announce the Fergus McCulla Psychological Support & Wellness Programme will be officially launched this month, and will be free of charge for all patients and families.

This programme will provide an additional layer to our peer support programme, and will be fully supervised by two experienced clinicians.

Please email Keith Cox, Director Patient Support at Keith.Cox@CRBF.org.au or Tania Rice-Brading Patient Support Coordinator at Taniarb@crbf.org.au should you wish to discuss or register for this programme.

Please see below a transcript of the speech delivered at the launch of the programme on Wednesday 1st December, at the Collaboration:  The key to unlocking advancements in sarcoma  Breakfast – delivered by Clinical Psychologist, Louise Hird.

My journey into the traumatic world of Sarcoma began as unexpectedly as everyone’s does.  My son, George, who you many of you heard speak at the CRBF corporate breakfast a couple of years ago, was very good friends with Cooper Rice Brading.  Cooper was great fun, had a wicked smile, played in the same cricket team as my son and was an avid Swans fan – he had a big future but his future also included Sarcoma.  His diagnosis came out of the blue, was sudden and we all thought he would be fine.  He wasn’t.  We knew nothing about Sarcoma – I am not sure I had even heard of it.  I now know that Cooper’s story is typical of many young Sarcoma sufferers. 

My son’s relationship with Cooper and involvement with the CRBF as an ambassador for the Foundation, kept myself and my family connected to Tania, Colin and Mitch  and the CRBF. Through that relationship, I have learnt a great deal about the perils of the diagnosis. More recently a dear friend who is in this room today, has been diagnosed and I have watched him and his family struggle with the same uncertainty, confusion and fear. Not only is very little known and very few treatments available but there is very little support for the individuals and their families diagnosed with sarcoma.

I am a Clinical Psychologist working in private practice.  I am very aware of the lack of funding and access generally to emotional and psychological support services in the community and how difficult it can be to navigate mental health services and find access to the right service or provider. I have learnt that Sarcoma patients and their families have very particular needs.  They  often feel very isolated as they don’t have the same access to support groups as other Cancer sufferers.  The support that they need is simply not available.  Sarcoma is extremely rare and that means that a diagnosis is extremely lonely and limited  research has been done in relation to the specific needs of people diagnosed with Sarcoma. This is changing thanks to our colleagues at Sock it to Sarcoma in WA.

I spoke at length with CRBF about this difficulty and began to work with my colleague Dr Lahvinya Kulaendra, a practicing psychiatrist, to develop a program that might address the very apparent gap in services available to Sarcoma sufferers.  Lahvinya and I have taught together on a number of programs working to develop psychological skills in young medical students, psychologists and psychiatrists. This project presented us with some unique challenges, these were not a group of people identified because of mental health difficulties but they were a group of people very much in need of support.  There is very little funding available to research and understand the scope of the unmet needs or to even clearly identify what the needs of Sarcoma patients are? And how could we fund such a service? By tapping into psychology students hoping to apply for Clinical Masters programs we found a group of people with the right skills and motivation to offer their services voluntarily. We approached the CRBF to financially support the development and delivery of a training program for the volunteers and they agreed. We selected our first group of volunteers who are all here – Merran Cunningham, Mitch Rice Brading, Nathan Salgo and Henry Foley –  and so this new project began to take shape. 

So many people have contributed their time voluntarily to make this new program possible.  Without this collaboration and without volunteers it could never have happened.

Many thanks to Keith Cox,  clinical nurse specialist whose deep knowledge and understanding of the nature and unpredicatable trajectory of Sarcoma and of the patient’s needs was invaluable; to Richard Boyle , sarcoma specialist and orthopeadic surgeon, for taking the time to teach us about the pathology, etiology and complex treatment and management of the illness, to Mandy Basson from SockItToSarcoma! who briefed us on the huge deficits in the emotional and psychological support offered to the patient’s and their families through the research her team is doing in WA. 

Finally, to the patients and families who joined us at the invaluable and at times heartbreaking round table discussions.  Here the patient journey was relayed,  to help us understand the deficit of information available, the limited treatment options, the loneliness and the isolation of being diagnosed with a rare cancer where there is little funding and support groups are limited.  And lastly many thanks to our volunteers for the amount of time they have given to this program and for their patience as the projected developed and changed. 

I am very excited that we are able to launch the Fergus McCulla Psychological  Support and Wellbeing Programme  today.  There is no doubt that there is great need in the Sarcoma community for such a program and I am very honored to have been part of this collaborative venture.  I hope that with further collaboration and funding we will be able to expand not only our medical understanding of the pathology, management and complexity of sarcoma treatment but also to offer individuals with Sarcoma support as they confront their diagnosis, treatments and suffering.’

‘Collaboration: The key to advancing sarcoma’ Breakfast Event

December 1, 2021. Botanic House, Royal Botanic Gardens Sydney

Not even the Omicron strain of Covid could eventually stop the “Collaboration: The key to unlocking advancements in sarcoma” breakfast from finally going ahead. After three false starts, spanning five months, 130 invited guests enjoyed a superb breakfast in the serene and picturesque surrounds of Botanic House, in the Royal Botanic Gardens Sydney.  This event was a collaboration between Sock it to Sarcoma! WA and the Cooper Rice-Brading Foundation and was proudly supported by the Weinert family and the Weinert Group of Companies.

The morning began with an unusually balmy 22 degree Sydney morning, with sunshine streaming through the trees and shrubbery, encasing Botanic House.  Guests arrived on time and in time to be seated and enjoy a sumptuous breakfast provided by the Trippas White Group.  We would like to acknowledge Allyson Wert, from the TWG, who oversaw the smooth running of the event, and was a delight to work in the months leading up to the breakfast.

The MC for the morning was Mitchell Rice-Brading, older brother of Cooper, and the consensus is, he did an outstanding job in his new role.  Mitch introduced Mandy Basson, Executive Director of SitS! who has worked tirelessly to advance sarcoma in Australia for over a decade, together with CRBF Chairman, Robert Beech- Jones. who spoke about the value of working together to advance sarcoma in Australia.

Professor Dorothy Keefe

The next speaker was Professor Dorothy Keefe, CEO of Cancer Australia, who was unable to attend the event due to a prior commitment with the Federal Minister for Health,  however she took the time to record an inspiring message which resonated deeply with the audience.

Dr Cleola Anderiesz, Deputy CEO Cancer Australia 

Dr Cleola Anderiesz, Deputy CEO of Cancer Australia, kindly stepped in for Professor Keefe, and held the room in the palm of her hand for the entire of her speech, her words echoing the theme of the breakfast, confirming the importance of working together to advance sarcoma.

Vale Celso Munoz

The mood of the breakfast then turned to a very sombre tone, as we each honoured the memory of Celso Munoz, who was to speak at the scheduled July event.  Celso had prepared his speech, which his wife Dr Mariana Sousa had found after he passed away on October 27th, from osteosarcoma.  Mariana felt Celso’s words should be heard, and they were read to our guests, and accompanied by a photographic tribute which can be viewed below.

Highly experienced and extremely personable media personality, performer and author, Gretel Killeen then took the stage to facilitate the research forum.  Gretel was simply outstanding in her role, and due to ongoing AV issues with our link to Western Australia, her professionalism and experience was tested to the limit, however she remained poised and in complete control throughout. Gretel led the panel with Sock it to Sarcoma’s Dr Simon Carroll from WA, Dr Vivek Bhadri, Chris O’Brien Lifehouse, ANZSA Board member, Associate Professor David Gyorki, Peter McCallum Cancer Centre,  Professor Michelle Haber AM , CCIA,  Professor Glenn Marshall AM, SCH & CCIA,  Professor David Thomas, GIMR & Omico, through 40 entertaining and informative minutes, with the panel sharing their innovative work and their hopes for the future of sarcoma.

It was then time for CRBF patient advocate Jack Gibson to take the stage, and to deliver such inspiring and heartfelt words, underpinning the importance and significance of hope, and providing deep insight into the past four years since his diagnosis.  You could literally hear a pin drop, as Jack spoke from the heart, and courageously recounted his innermost thoughts on the the role hope plays at various intervals from diagnosis and beyond, not only for him, but for all sarcoma patients.

A tribute to Fergus McCulla

A tribute to Fergus McCulla followed.  Fergus was and is a much loved member of the CRBF community, who lost his life to sarcoma in August of 2021.  We were honoured to have Fergus’ family Jane, Norman and Anna, join us on the morning, and for them to be present for the launch of the Fergus McCulla Psychological Support and Wellbeing programme.  Fergus was a keen and talented musician and an original song he penned and sang, was used as the basis for a photographic tribute, which you can listen to by clicking the link below.

The Fergus McCulla Psychological Support and Wellbeing Programme

Clinical Psychologist, Louise Hird, together with Psychiatrist Dr Lahvinya Kulaendra, created and incepted the psychological support programme, which will provide fully supervised emotional support, free of charge to all sarcoma patients and families nationally.  Louise provided a polished overview of the programme and its purpose for our guests, thanking our graduate volunteers, Nathan Salgo, Henry Foley, Merran Cunningham, and Mitchell Rice-Brading, together with our legal team, Ross McLean and Michael Furlong for the many hours placed into the ensuring all legal requirements were met prior to its launch.

The Wipfli Family Sarcoma Research Grant

Media personality Michael “Wippa”. Wipfli, provided a lighter segment, speaking about his time on Celebrity Apprentice, and what the experience meant to him personally. Wippa on behalf of his beautiful wife Lisa, also attending the breakfast, presented a cheque to Dr Emmy Fleuren for $183,000 which represented his outstanding challenge win on Celebrity Apprentice Australia. He also presented a cheque to Molly Croft and Australian netball star, Amy Parmenter for the Tie Dye Project to aid paediatric/AYA sarcoma research in Australia.

Mr Andrew Hagger, CEO Minderoo and the Minderoo Foundation 

Sock it to Sarcoma and the Cooper Rice-Brading Foundation were very excited at the prospect of having Minderoo CEO, Andrew Hagger, present to our guests on the morning.  The universe did manage to throw a number of significant curved balls our way, including WA border closures, which saw Andrew willingly offer to deliver his very important words via livestream. 

The gods of AV had other ideas and the instability of the live stream connection due to the current weather conditions continent wide, saw the line drop out consistently.  Andrew, as a highly seasoned professional had the foresight to record his speech, however nothing it appeared was going to go well in this segment, and the taped message was not played at the event.  This was so terribly  disappointing not only to the two hosting organisations, but to the numerous people attending the breakfast, who had wanted to hear Andrew speak.

We wish to also recognise the time and expertise Bruce Mansfield from the Minderoo Foundation, has invested in assisting CRBF, in building strategies around his vast experience with the Brain Cancer Mission.   This invaluable advice led to the joint submission with SitS! and the National Sarcoma Initiative.

We would like to extend our heartfelt thanks to Andrew Hagger and Bruce Mansfield for their high level support, and their willingness to assist both organisations in advancing sarcoma in Australia.

Our thanks to those who have made significant contributions to sarcoma in Australia

An important segment on the morning highlighted a number of significant contributions to sarcoma research over past years, including the Dr Matthew Fisher Research Fund  which amassed in excess of $90,000 and was to be presented to Professor David Thomas at the scheduled July event, by Dr Fisher’s wife, Naomi Chun and his daughters, Sylvie and Vivian.  Dr Fisher lost his life to rhabdomyosarcoma in January of 2021, after a relatively brief but very courageous battle with this savage sarcoma sub-type.  As with each of us in the room on Wednesday, Dr Fisher and his family were and are very passionate about funding research for an eventual cure.

We also wish to mention the Wipfli Family Sarcoma Research Grant, the Daniel Allchin Race for a Cure, conducted by the Allchin family, the Fell Foundation, Running for Tom, in memory of Tom Hardyman, Vince’s Sprint for Sarcoma, The Alex Williams Memorial Fund donated by the Williams family, Dr Mariana Sousa, daughter Mia and the Salesforce team in honour of Celso Munoz, The McCulla Family in memory of Fergus Mculla, and the Weinert family & the Weinert Group of Companies.  We also wish to acknowledge not only those in the room – far too numerous to mention, who have contributed enormously over past years, but also the Australian public, who have embraced this cancer, despite very few ever being personally affected.

Special thanks

Special thanks to Tom Molloy who undertook photography for the event, providing us all with some very special memories. Also to Martin Rossleigh, Siobhan Shaw, Di Lawrance and Emma Duncan for their ongoing assistance on the morning.

3 young men & a very special childhood friendship


A very special childhood friendship

 

After a valiant three year battle against a Rhabdomyosarcoma,Tom Hulston and Rob Stein’s childhood friend Fergus McCulla, tragically passed away last month at the age of 31.

A life tragically taken too soon by this devastating disease.

Tom and Rob considered themselves to be the lucky ones to have spent some of the best moments of their lives creating wonderful memories with Fergus from the time they met at Barker College Junior School over 20 years ago.

“Fergus suffered through three years of extremely invasive surgeries, oppressive chemotherapy regimens and exhausting radiation treatments, but in a true testament to his character, he never lost his sense of humour and kindness to other people. He was always going out of his way to make sure others were ok and never once complained about the unspeakably difficult time he was going through”, Tom and Rob recently wrote.

On the 19th of September, Rob and Tom courageously ran the Copenhagen Half Marathon in Fergus’ honour.  Their target was originally $2000 however when this post was published, they had raised in excess of a very impressive amount of $4000.

We would like to extend our deepest gratitude to Tom and Rob, who whilst in the depths of grief  having loss of their childhood friend, ran this gruelling event to raise funds to assist those living with a sarcoma diagnosis, in Fergus’ honour. 

“We will never forget you Fergus and we will forever be inspired by your courage and kindness.” (Tom Hulston and Rob Stein, September 2021)

 

 

Precision medicine & phosphoproteomics


Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas.  

Highlights

•  Outcomes for pediatric/AYA sarcoma patients are poor and no targeted treatments exist.
•  Pediatric and AYA sarcoma patients rarely harbor actionable genomics aberrations.
•  Phosphoproteomics captured novel actionable drivers missed by genomics screens

•  Phosphoproteomics explained critical targeted drug mechanism of action/resistance.

•  Outcomes in personalized medicine platforms may be enhanced by phosphoproteomics.

Press the link below to read more:

https://www.sciencedirect.com/science/article/pii/S0304419X21001116

Paediatric/AYA Cancer Researcher Dr Emmy Fleuren


Dr Emmy Fleuren is a research scientist specialising in paediatric/AYA sarcomas.

Emmy’s sarcoma-centred research journey started in the Netherlands at the Radboud UMC in 2010, over eleven years ago.   Since then, she has been undertaking paediatric and AYA sarcoma research across the globe at various world-class research institutions.  These include the Institute of Cancer Research (ICR) and Royal Marsden Hospital (RMH), London, UK, Monash University, Melbourne, and currently the Children’s Cancer Institute and the ZERO Childhood Cancer precision medicine program here in Sydney.

Cancer as a disease, has always fascinated Emmy.  “How is it, that at a given point in time, your body’s own cells start to act weirdly and grow uncontrollably? she questions.   It is very different from a viral or bacterial disease, where we know what is causing it, and the why and the how of cancer always piqued my curiosity.”

It is no secret Emmy loves what she does.

When asked why she explained, “We are doing experiments/analysing data on a daily basis that have the potential to ultimately change the outcome of a young patient with cancer. Because my studies are embedded within the ZERO Childhood Cancer Program, which is Australia’s, and arguably the world’s, most comprehensive precision medicine platform aimed to provide tailored treatment recommendations for individual childhood cancer patients, every result that we get can have an impact on a patient’s life. Being able to get meaningful results for a patient who needs our help right now is incredibly rewarding, and I feel so privileged to be part of a program that is able to do just that.”

Emmy has been driven by the numbers of young sarcoma patients she met whilst undertaking her PhD research in the Netherlands, which has placed a very personal edge on everything she does.

“They all shared the same frustration”, said Emmy: “Why am I still treated with a protocol from the nineties?”  Emmy has seen first- hand the detrimental effects these treatments can have on young patients, yet these treatments still were not enough to cure all of them. That left a lasting impression, and that is when I decided to go all-in on sarcoma research.

So how does this talented researcher, and mother of one see as the key to ongoing success?  In addition to securing the critical funds needed to make research possible, we need to attract and retain the brightest young researchers, and to have them get them as enthusiastic about sarcoma research as Emmy is.

“We can only go far if we go together!” said Emmy.

The ZERO Childhood Cancer Program, which is Australia’s, and arguably the world’s, most comprehensive precision medicine platform aims to provide tailored treatment recommendations for individual childhood cancer patients. In addition to including whole genome and whole transcriptome molecular profiling, the programme is now  looking at methylation profiles.  It has an incredibly successful and dedicated ‘Preclinical Drug Testing Core’ (PDTC). In the PDTC, the patient’s own tumour cells are grown the laboratory and in mouse avatar models, to test a wide range of clinically applicable drugs. A number of drugs have already been identified and ‘hits’ that were not predicted by the molecular profiling revealed, underlining the importance of these assays.

“Not many childhood cancer patients in the world have the opportunity to enrol in such a comprehensive program, particularly not patients suffering from rare diseases like sarcoma. This program has been a major determining factor for me deciding to make the move to Australia with my family in 2019, including our son who was ten months old at the time” said Emmy.

Closely linked to this program, my research is centred on building novel pipelines to be able to give targeted treatment recommendations to even more patients. Thanks to the Cooper Rice-Brading Foundation and The Kids’ Cancer Project, we will be able to perform a completely novel line of investigation, phosphoproteomics (looking at targets that are actually “switched on” and driving the cancer), while the program expands to ultimately include childhood cancer patients of all stages of their disease (from diagnosis, to relapse, to metastasis). This gives the team at Zero, CCIA a truly unique opportunity to screen for the presence of activated targets at different moments in time, which is incredibly exciting. One question Emmy in particular would like answered is, “can we start using novel, targeted therapies directed against activated targets earlier in the disease (for example at diagnosis), sparing these patients the side-effects of toxic chemotherapies and invasive surgeries?”

What really excites Emmy is that tangible progress is being made for sarcoma patients, in real time. The sarcoma research that she performed prior to her move to Australia was more laboratory-based, using sarcoma patient cell line models that have been around for a while, and any result found would not benefit that particular patient anymore. The next step for those studies has always been facilitating a clinical translation of results; bringing our laboratory findings to the actual patients.

Working within ZERO is completely different for Emmy. Every discovery made, has the potential to have an actual clinical impact for that patient. This type of research in “real-time” is what Emmy always wanted to do, and in Australia within this innovative research at the ZERO Childhood Cancer Program she can do just that. Precision medicine programs elsewhere in the world are also not as comprehensive as ZERO, who have the best chance of identifying a more specific, less toxic treatment for a sarcoma patient, by not only looking at the molecular profile of their tumour, but also performing state-of-the-art drug-screens on the patient’s own cell grown in our lab, and establishing unique mouse avatar models for the patient. It really is an amazing opportunity for young sarcoma patients in Australia, as no-one else in the world has access to such a diverse screening platform.

Emmy is working with a cohort of paediatric/AYA sarcoma specialists in Australia to fulfil hopes for the future of sarcoma which are:

    • Having ZERO more easily accessible to all childhood/AYA sarcoma patients, including those treated in adult centres.
    • From our own research: identified new, activated targets that can be switched off with specific, non-toxic drugs for patients that are currently missing out.
    • To have integrated my sarcoma research lines (including looking at activated targets and unexpected preclinical drug responders) to the mainstream ZERO program, and thereby increasing the number of patients receiving a targeted therapy recommendation.

What would Emmy’s greatest wish as a researcher be for the future of young cancer patients in Australia?

“That we will be able to make childhood cancer a curable disease for every type of childhood cancer, using drugs that are not only more effective, but also less toxic.”

CRBF together with The Kids Cancer Project  are delighted to support Emmy’s work and that of her remarkable team, within the Phosphoproteomic sarcoma specific trial under the auspices of the Zero Children’s Cancer Programme.

R U OK? Day Checking in on a loved one…


Today, on RU OK? day, we emphasise the importance of reaching out to those around you. In particular, to those who you know are going through a tough time, whether it be cancer, COVID, or life-induced.

Reaching out to someone never has to be a big deal. How good does it feel when someone tells you what a good friend you are to them? Reminding someone of this, can create the space for future conversations if they need to be had. And, it reminds them they aren’t alone.

And at CRBF, we are always here for our patients – no exceptions. We currently have an array of different support services in place, and in the not-too-distant-future, we will be able to offer even more. But for now, never hesitate to contact us through phone, email, or social media.

Checking in on those around you isn’t an annual event, but given the current climate in Australia, it’s a timely reminder.